Psychiatry’s diagnostic bible is finally getting a biological upgrade
The American Psychiatric Association is preparing to modernise the DSM, the standard diagnostic manual for mental illness, by incorporating biology for the first time since its creation. The current edition, DSM-5, published in 2013, has been criticised for relying solely on clinical judgement of symptoms without objective biological measures, which critics argue risks medicalising ordinary suffering and undermines the reliability of psychiatric diagnoses. This shift matters because it could reshape how conditions are diagnosed and researched worldwide, given the DSM's central role for clinicians and scientists alike.
The article's author, a member of the DSM's strategic committee from May 2024 to August 2026, explains that reliable biomarkers, objective measures such as blood tests or scans used routinely in other areas of medicine, barely exist for mental illness, with the notable exception of certain proteins linked to Alzheimer's disease. This is because the biological changes underlying conditions such as depression, anxiety, schizophrenia and bipolar disorder are subtle, poorly understood, and entangled with strong environmental factors like family history and trauma. Psychiatric disorders are also increasingly understood as overlapping behavioural syndromes rather than discrete illnesses, with conditions such as major depressive disorder and schizophrenia likely comprising several biologically distinct subgroups, making a single unifying biomarker for any one diagnosis unlikely.
- DSM's next edition will begin integrating biology into psychiatric diagnosis
- Current DSM-5 criticised for lacking objective biological measures
- Reliable biomarkers for mental illness remain scarce and hard to isolate
New here? Start with this
The DSM is a manual published by the American Psychiatric Association that clinicians use to classify mental health conditions. Its current edition, DSM-5, dates from 2013, and diagnoses are based mainly on patterns of symptoms and clinical judgement.
Unlike many other areas of medicine, psychiatry has few biological measures, such as blood tests or scans, that can reliably identify a condition. Researchers are still learning how biology, life experiences and family history interact, and people given the same diagnosis may have different underlying patterns.
Changes to the manual could affect how mental health conditions are diagnosed and studied around the world. The challenge is to assess whether biological measures can help when conditions overlap and may not have a single cause or marker.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Psychiatry requires objective biological measures to become a reliable science comparable to other medical fields. Symptom-based diagnosis is inherently subjective and prone to misdiagnosis; biomarkers would ground clinical judgement in verifiable data and improve consistency across practitioners and nations. Even though reliable biomarkers remain elusive for most conditions, pursuing biological understanding is essential for scientific progress and developing effective treatments, and the existence of biomarkers for some conditions like Alzheimer's shows the path forward is achievable.
The case against
Mental illness differs fundamentally from other medical conditions because it is irreducibly entangled with environment, trauma, and social context in ways that resist biological reduction. The story itself acknowledges that reliable biomarkers barely exist for most psychiatric conditions, which suggests that forcing a biological framework onto incompletely understood phenomena risks creating false certainty. The strength of the current symptom-based approach is that it captures the lived, relational reality of human distress; replacing clinical observation with premature biologization could pathologise normal suffering and lose the nuance essential to genuine care.